纳入标准:
|
参照《慢性乙型肝炎诊断标准》(2015版)和《原发性肝癌诊断标准诊断标准》(2000年版),慢性乙型肝炎患者:既往有乙型肝炎病史或HBsAg阳性超过6个月,现HBsAg和(或)HBV DNA仍为阳性者,ALT持续或反复增高者。①慢性乙型肝炎纤维化/肝硬化代偿期患者:既往有乙型肝炎病史或HBsAg阳性,伴肝细胞合成功能障碍或门静脉高压但无出血、无腹水;②慢性乙型肝炎肝硬化失代偿期患者:既往有乙型肝炎病史或HBsAg阳性,伴食管胃底静脉曲张破裂出血、肝性脑病、腹水等;③慢性乙肝病毒相关肝癌患者:既往有乙型肝炎病史,AFP>400ug/L,能排除活动性肝病、妊娠、生殖系胚胎源性肿瘤及转移性肝病,并能触及坚硬及有肿块的肝脏或影像学检查具有肝癌特征性占位性病变;AFP<400ug/L者,有两种影像学检查具有肝癌特征占位性病变或有两种肝癌标志物(AFP异质体、异常凝血酶原、r-谷氨酰转肽酶同工酶II及a-L-岩藻糖苷酶等)阳性及一种影像学检查具有肝癌特征性占位性病变;④健康体检人员;血常规、常规生化(Glu, BUN,Cr, ALT,AST),肿瘤标志物(AFP,CEA,CA125, CA153,PSA,CA724,CA199), 胸部影像和腹部超声均正常,无肿瘤疾病史,无自身免疫性疾病,无过敏性疾病,无免疫相关疾病,表观健康。
|
Inclusion criteria
|
According to the diagnostic criteria for chronic hepatitis B (2015 Edition) and the diagnostic criteria for primary liver cancer (2000 Edition), patients with chronic hepatitis B: those with a history of hepatitis B or HBsAg positive for more than 6 months, who are still positive for HBsAg and / or HBV DNA, and whose ALT is continuously or repeatedly increased. ① Patients with chronic hepatitis B fibrosis / cirrhosis in the compensatory stage: Patients with previous history of hepatitis B or HBsAg positive, with dysfunction of hepatocyte synthesis or portal hypertension but no bleeding or ascites; ② Decompensated patients with chronic hepatitis B cirrhosis: previous history of hepatitis B or HBsAg positive, accompanied by esophageal and gastric variceal bleeding, hepatic encephalopathy, ascites, etc; ③ Patients with chronic hepatitis B virus related liver cancer: they have a history of hepatitis B, AFP > 400ug / L, can exclude active liver disease, pregnancy, germline embryogenic tumor and metastatic liver disease, and can touch hard and lumpy liver or imaging examination with characteristic space occupying lesions of liver cancer; In the patients with AFP < 400ug / L, there were two kinds of space occupying lesions with liver cancer characteristics or two kinds of liver cancer markers (AFP heterogeneity, abnormal prothrombin, r-glutamyltranspeptidase isozyme II and a-L-Fucosidase, etc.) positive and one kind of space occupying lesions with liver cancer characteristics on imaging examination; ④ Health examination personnel; Blood routine, routine biochemistry (Glu, BUN, Cr, ALT, AST), tumor markers (AFP, CEA, CA125, CA153, PSA, CA724, CA199), chest imaging and abdominal ultrasound were normal, without tumor disease history, autoimmune disease, allergic disease, immune related disease, and apparent health.
|
Exclusion criteria:
|
Combined with other viral infections, such as HIV, HCV, HDV infection, oral immunosuppressants, organ transplantation, and other diseases affecting the immune system;
Baseline survey: antiviral treatment, alcoholic hepatitis, alcoholic fatty liver, obese fatty liver, etc.
|